PTE - PolarityTE Receives Unique HCPCS Q-Code for SkinTE for
Nov 21, 2018 13:10:00 GMT
icemandios, thought013, and 2 more like this
Post by c2crusher on Nov 21, 2018 13:10:00 GMT
PolarityTE Receives Unique HCPCS Q-Code for SkinTE for Product Reimbursement from CMS
ir.polarityte.com/profiles/investor/ResLibraryView.asp?ResLibraryID=89208&BzID=2361&G=1148
SALT LAKE CITY, Nov. 21, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that the Centers for Medicare and Medicaid (CMS) has assigned a unique product Q-code under the Healthcare Common Procedure Coding System (HCPCS) for SkinTE™. This HCPCS Q-code will help facilitate the reimbursement for SkinTE.
PolarityTE (PRNewsfoto/PolarityTE, Inc.)
"Establishment of a unique Q-code is impactful to our reimbursement strategy to provide access for patients and providers to SkinTE. SkinTE, an autologous, homologous skin product, is truly unique in today's market," commented Sharon Whalen, Vice President of Market Access of PolarityTE.
"PolarityTE looks forward to increasing access to our revolutionary product through advancement of our reimbursement strategy with this code. Patients and providers need better solutions for tissue repair, and we will continue to work on all fronts to ensure we can deliver better therapies to improve health care and lower costs," said Denver M. Lough, M.D., Ph.D., Chairman and Chief Executive Officer of PolarityTE.
The HCPCS Q-code for SkinTE will be billed as Q4200, effective January 1, 2019.
Welcome to the Shift®.
Crusher
ir.polarityte.com/profiles/investor/ResLibraryView.asp?ResLibraryID=89208&BzID=2361&G=1148
SALT LAKE CITY, Nov. 21, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that the Centers for Medicare and Medicaid (CMS) has assigned a unique product Q-code under the Healthcare Common Procedure Coding System (HCPCS) for SkinTE™. This HCPCS Q-code will help facilitate the reimbursement for SkinTE.
PolarityTE (PRNewsfoto/PolarityTE, Inc.)
"Establishment of a unique Q-code is impactful to our reimbursement strategy to provide access for patients and providers to SkinTE. SkinTE, an autologous, homologous skin product, is truly unique in today's market," commented Sharon Whalen, Vice President of Market Access of PolarityTE.
"PolarityTE looks forward to increasing access to our revolutionary product through advancement of our reimbursement strategy with this code. Patients and providers need better solutions for tissue repair, and we will continue to work on all fronts to ensure we can deliver better therapies to improve health care and lower costs," said Denver M. Lough, M.D., Ph.D., Chairman and Chief Executive Officer of PolarityTE.
The HCPCS Q-code for SkinTE will be billed as Q4200, effective January 1, 2019.
Welcome to the Shift®.
Crusher